Group 1 - The company Boji Pharmaceutical has received approval for its tadalafil tablets in 5mg, 10mg, and 20mg dosages [1] - The approved tadalafil products are marketed under the brands "Gun Ge" and "Weil Chang" [1]

（文章来源：证券日报） 证券日报网讯博济医药8月13日在互动平台回答投资者提问时表示，公司通过在国外成立子公司，组建 国外业务部门，引入有国际业务经验的人才，积极拓展国外临床业务。 ...

证券日报网讯博济医药8月13日在互动平台回答投资者提问时表示，公司控股子公司九泰药械是一家专 注于医疗器械第三方外包服务的CRO公司，主要为客户提供医疗器械相关的临床试验以及注册申报服 务，目前暂无脑机接口领域相关的项目。九泰药械积极关注脑机接口相关领域，也有能力为脑机接口医 疗器械的注册及临床试验提供全流程服务。 （文章来源：证券日报） ...

格隆汇8月13日丨博济医药(300404.SZ)在互动平台表示，公司控股子公司九泰药械是一家专注于医疗器 械第三方外包服务的CRO公司，主要为客户提供医疗器械相关的临床试验以及注册申报服务，目前暂 无脑机接口领域相关的项目。九泰药械积极关注脑机接口相关领域，也有能力为脑机接口医疗器械的注 册及临床试验提供全流程服务。 ...

格隆汇8月13日丨博济医药(300404.SZ)在互动平台表示，公司控股子公司九泰药械是一家专注于医疗器 械第三方外包服务的CRO公司，主要为客户提供医疗器械相关的临床试验以及注册申报服务，目前暂 无脑机接口领域相关的项目。九泰药械积极关注脑机接口相关领域，也有能力为脑机接口医疗器械的注 册及临床试验提供全流程服务。 ...

公司回答表示：您好，公司通过在国外成立子公司，组建国外业务部门，引入有国际业务经验的人才， 积极拓展国外临床业务。感谢您的关注！ 金融界8月13日消息，有投资者在互动平台向博济医药提问：公司有没有在积极拓展国外市场？ ...

天眼查商业履历信息显示，博济医药科技股份有限公司，成立于2002年，位于广州市，是一家以从事研 究和试验发展为主的企业。企业注册资本38198.9708万人民币，实缴资本10000万人民币。公司法定代 表人为王廷春。 通过天眼查大数据分析，博济医药科技股份有限公司共对外投资了39家企业，参与招投标项目112次， 知识产权方面有商标信息49条，专利信息47条，此外企业还拥有行政许可44个。 金融界消息 截至2025年8月11日收盘，博济医药（300404）报收于11.0元，上涨1.38%，换手率6.71%， 成交量18.84万手，成交金额2.06亿元。 资金流向方面，今日主力资金净流出1136.01万元，占比成交额5.51%。其中，超大单净流出132.40万 元、占成交额0.64%，大单净流出1003.60万元、占成交额4.87%，中单净流出流出661.63万元、占成交 额3.21%，小单净流入1797.64万元、占成交额8.73%。 博济医药最新一期业绩显示，截至2025一季报，公司营业总收入1.39亿元、同比减少17.06%，归属净利 润390.06万元，同比减少76.38%，扣非净利润169.79万元，同 ...

证券日报网讯博济医药（300404）8月6日在互动平台回答投资者提问时表示，中药研发服务是公司特色 业务领域，公司是目前市场极少数能够提供中药研发一体化服务的CRO公司。近几年公司中药业务发 展迅速，服务项目、订单及收入稳步增加，随着国家对中医药产业的重视程度不断提升，中医药行业也 将迎来发展的新机遇。 ...

Core Viewpoint - The company, Boji Pharmaceutical, is primarily focused on innovative drug development, with a diverse portfolio that includes chemical drugs, biological drugs, and traditional Chinese medicine [1] Group 1: Drug Development - The company has completed Phase III clinical trials and launched innovative drugs such as recombinant human albumin injection (from rice) and sildenafil hydrochloride tablets [1] - A self-developed traditional Chinese medicine new drug (Category 1.1) has completed Phase III clinical trials, while a collaborative development project in the same category is currently in Phase III [1] Group 2: Research and Technology - The company has established databases related to researchers, clinical trial institutions, and clinical trial projects to enhance its research capabilities [1] - The company is actively exploring the application of AI technology in drug development to improve efficiency and quality, with current usage in both preclinical and clinical operations [1]

Core Insights - The company, Boji Pharmaceutical, focuses on innovative drug development, with a diverse portfolio including chemical drugs, biological drugs, and traditional Chinese medicine [1] - The company has successfully completed Phase III clinical trials and launched innovative drugs such as recombinant human albumin injection and sildenafil citrate tablets [1] - The company is actively exploring the application of AI technology in drug development to enhance efficiency and quality, with ongoing use in both preclinical and clinical operations [1] Group 1 - The company has numerous projects in service, primarily centered on innovative drugs [1] - The company has completed Phase III clinical trials for several innovative drugs and has a traditional Chinese medicine new drug in Phase III clinical trials [1] - The company has established databases related to researchers, clinical trial institutions, and clinical trial projects [1] Group 2 - The company is transferring its self-developed projects to external clients after achieving certain technical results, allowing clients to continue development [1] - The company is exploring more applications of AI technology in drug development beyond current uses [1] - The company is preparing to establish a real-world database for AI models to enhance innovative drug clinical research [3]